LICENSE AGREEMENT by and between TITAN PHARMACEUTICALS, INC. and BRAEBURN PHARMACEUTICALS SPRL dated December 14, 2012License Agreement • February 28th, 2013 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 28th, 2013 Company Industry JurisdictionTHIS LICENSE AGREEMENT (the “Agreement”) is made as of December 14, 2012 (the “Effective Date”), by and between TITAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080-1921, United States (“Titan”), and BRAEBURN PHARMACEUTICALS SPRL, a limited liability company organized and existing under the laws of Belgium and having its principal office at Jipfa Building, 3rd Floor, 142 Main Street, Tortola, British Virgin Islands ( “Braeburn”).
LICENSE AGREEMENT by and between TITAN PHARMACEUTICALS, INC. and BRAEBURN PHARMACEUTICALS SPRL dated December 14, 2012License Agreement • December 19th, 2012 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Contract Type FiledDecember 19th, 2012 Company Industry JurisdictionTHIS LICENSE AGREEMENT (the “Agreement”) is made as of December 14, 2012 (the “Effective Date”), by and between TITAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080-1921, United States (“Titan”), and BRAEBURN PHARMACEUTICALS SPRL, a limited liability company organized and existing under the laws of Belgium and having its principal office at Jipfa Building, 3rd Floor, 142 Main Street, Tortola, British Virgin Islands ( “Braeburn”).